ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
Japan headquartered pharmaceutical company Shionogi & Co. has received approval from the Taiwan Food and Drug Administration (TFDA) for FETROJA (cefiderocol) in the treatment of complicated urinary tract infections, including pyelonephritis, and hospital-acquired pneumonia (including hospital-acquired bacterial pneumonia and ventilator-acquired associated bacterial pneumonia) caused by susceptible Gram-negative microorganisms. This approval applies to adult patients.
PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan
Shionogi Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open
With the help of ad agency FCBCURE, the biopharma added generative artificial intelligence to its already-running infectious disease “Warriors” campaign to create personalized images for people at medical conferences.
Japan's Shionogi establishes JV with US-based Apnimed to treat sleep disorders
Apnimed Announces Launch of Joint Venture with Shionogi
An overall success rate of 28.7% was seen at day 42, the primary endpoint, and 27.2% at day 84, as determined by a data review committee (DRC) using the EORTC-MSG criteriaThe success rate rose to...
Shionogi Presents New Ensitrelvir COVID-19 Data Supporting Effectiveness in Real-World and Clinical Settings at IDWeek 2023